New product newswire: February 2, 2006

The FDA gave marketing approval to ZLB Behring, King of Prussia,Pa., for an immunoglobulin (Ig) replacement therapy that can beself-administered by patients at home. Vivaglobin (immune globulinsubcutaneous [human]), indicated for treating patients with primaryimmunodeficiency, delivers antibodies subcutaneously, as analternative to intravenous infusions of immunoglobulin, to fightlife-threatening infections. The firm can be reached at (610)878-4000.